Finance

Lists
MARKSANS:NSE
Marksans Pharma Ltd
310,80 INR
+0,96%
(+2,95) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MARKSANS...
Open
308,10 INR
High
313,50 INR
Low
306,00 INR
Mkt. cap
140,84 მლრ.
Avg. vol.
2,25 მლნ.
Volume
768,00 ათ.
Dividend
0,29%
Quarterly dividend
0,22 INR
Ex-dividend date
20 აგვ. 2026
P/E ratio
27,24
52-wk high
350,95 INR
52-wk low
155,00 INR
EPS
11,41 INR
Shares outstanding
409,31 მლნ.
No. of employees
2 ათ.
Open
308,10 INR
High
313,50 INR
Low
306,00 INR
Mkt. cap
140,84 მლრ.
Avg. vol.
2,25 მლნ.
Volume
768,00 ათ.
Dividend
0,29%
Quarterly dividend
0,22 INR
Ex-dividend date
20 აგვ. 2026
P/E ratio
27,24
52-wk high
350,95 INR
52-wk low
155,00 INR
EPS
11,41 INR
Shares outstanding
409,31 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
About Marksans Pharma Ltd
CEOმარკ ბი სალდანჰა
Employees1,68 ათ.
Founded1992
Headquarters-
SectorPharmaceutical industry
Last report
13 აგვ. 2026
Fiscal period
Q1 2027
3,47 INR / 3,30 INR
+5,15%beat
Revenue / Est. (INR)
8,41 მლრდ. / 8,50 მლრდ.
-1,11%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
7,20 მლრდ.
7,54 მლრდ.
8,56 მლრდ.
8,41 მლრდ.
Cost of goods sold
3,09 მლრდ.
3,16 მლრდ.
4,51 მლრდ.
3,43 მლრდ.
Cost of revenue
3,09 მლრდ.
3,16 მლრდ.
4,51 მლრდ.
3,43 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,04 მლრდ.
1,12 მლრდ.
1,21 მლრდ.
1,14 მლრდ.
Operating expense
2,94 მლრდ.
3,02 მლრდ.
2,33 მლრდ.
3,09 მლრდ.
Total operating expenses
6,03 მლრდ.
6,18 მლრდ.
6,85 მლრდ.
6,53 მლრდ.
Operating income
1,18 მლრდ.
1,36 მლრდ.
1,72 მლრდ.
1,88 მლრდ.
Other non operating income
215,72 მლნ.
201,44 მლნ.
-441,86 მლნ.
63,99 მლნ.
EBT including unusual items
1,33 მლრდ.
1,51 მლრდ.
2,00 მლრდ.
2,07 მლრდ.
EBT excluding unusual items
1,33 მლრდ.
1,51 მლრდ.
1,99 მლრდ.
2,07 მლრდ.
Income tax expense
341,95 მლნ.
369,34 მლნ.
509,66 მლნ.
471,64 მლნ.
Effective tax rate
25,65%
24,52%
25,48%
22,83%
Other operating expenses
1,64 მლრდ.
1,65 მლრდ.
881,88 მლნ.
1,70 მლრდ.
Net income
982,50 მლნ.
1,13 მლრდ.
1,48 მლრდ.
1,57 მლრდ.
Net profit margin
13,64%
15,01%
17,30%
18,69%
Earnings per share
-
2,50
3,27
3,47
Interest and investment income
-
-
276,78 მლნ.
-
Interest expense
-58,15 მლნ.
-59,35 მლნ.
-63,11 მლნ.
-
Net interest expenses
-58,15 მლნ.
-59,35 მლნ.
213,67 მლნ.
-
Depreciation and amortization charges
269,16 მლნ.
243,27 მლნ.
242,88 მლნ.
248,64 მლნ.
EBITDA
1,43 მლრდ.
1,50 მლრდ.
1,87 მლრდ.
2,04 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები